Destiny Pharma is dedicated to the discovery, development and commercialisation of new antimicrobials that have unique properties to improve outcomes for patients and the delivery of medical care into the future.
Positive update on partner deals
Destiny have announced a trading update that includes a bolus of progress on the partnering of its...
Read moreValidation for microbiomes
With the first ever FDA approval for a faecal microbiome drug the door has been opened for other...
Read moreAn educational R&D day
Destiny recently held a R&D Day and the presentations on its two Phase 3-ready products from key...
Read moreInterim 2022 results: oodles of progress
Destiny reported its H1 2022 financial results and provided an update on its pipeline progress. We...
Read moreGreater regulatory clarity given
Destiny have announced an update on the discussions with the FDA on the Phase 3 development plans...
Read moreA useful addition to XF-73’s profile
Destiny have announced a new XF-73 research programme on the prevention of oral mucositis (OM) in...
Read moreResults bring welcome detail and no surprises
After the recent fundraising, there were no surprises in Destiny’s FY 2021 financials which...
Read moreNTCD-M3 competitors stumble while issue approved
With the recently announced fundraising approved at Destiny’s GM, and the competition to Destiny’s...
Read moreFundraising to bolster its positioning
Destiny have announced a conditional fundraising at 50p per share that includes a placing,...
Read moreVery welcome regulatory clarity
Destiny Pharma has announced details of positive feedback from the European Medicines Agency (EMA)...
Read moreM3’s profile rising further
In a spree of positive updates to start 2022, Destiny Pharma begins the year with the profile of...
Read more
Register to be first
Get research on the companies that interest you straight to your inbox
